ARTICLE | Company News
XEN, MLNM topoisomerase deal
December 17, 2001 8:00 AM UTC
Xenova (LSE:XEN; XNVA) said it exclusively licensed to Millennium (MLNM) North American development and marketing rights for its topoismoerase inhibitor program treating solid tumor cancers. The progr...